TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/02/2025
Voltar para busca
Dado oficial do USPTO
ATAC
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
54
Atualização mais recente
04/02/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 42, 44
Data de depósito
21/05/2019
Data de registro
01/11/2022
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
01/11/2022
Última transação
04/02/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use, Foreign priority
Código do desenho
4
Tipo de titular
99
Localização do titular
Ladenburg, DE
Examinador
STURMAN, MELISSA M
Unidade examinadora
N70
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Heidelberg Pharma Research GmbH
Representantes
Todd A. Sullivan Hayes Soloway P.C.
Classificação técnica
Classes Nice
Classe 5Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparationsanti-cancer and immunosuppression preparations; pharmaceuticalsanti-cancer and immunosuppression preparations; chemico-pharmaceutical preparationschemical preparations for medical purposes for the treatment of cancer and immunosuppression; pharmaceutical preparations and substancespharmaceutical products for the treatment of cancer and immunosuppression; pharmaceutical preparationsanti-cancer preparations for veterinary use; chemical preparations for pharmaceutical purposeschemical preparations for the treatment of cancer and immunosupression; pharmaceutical preparations for human usepharmaceutical preparations for human use in the treatment of cancer and immnunosupression; pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in chemotherapy; pharmaceutical preparations for the treatment of cancer and immunosuppression; pharmaceutical preparations and substances for the treatment of cancer and immunosuppression; pharmaceutical preparations and substances for use in oncology; diagnostic preparations for medical purposes; diagnostic agents for pharmaceutical use; diagnostic agents for medical use; diagnostic preparations for veterinary purposes; clinical diagnostic reagents for medical use; diagnostic chemical reagents for medical use; anti-cancer drugsanti-cancer preparations; pharmaceutical compounds for treating cancer and immunosuppression; anti-cancer preparations; anti-cancer preparations of chemical origin; biopharmaceuticalsanti-cancer preparations for the treatment of cancer and immunosuppression; pharmaceutical preparations and substances for the prevention of cancer; chemotherapeutics; antibodies being pharmaceutical preparations for the treatment of cancer and immunosuppression; all the aforesaid goods exclusively relating to the fields of oncology and/or immunosuppression with agents including amatoxin
Classe 42
Pharmaceutical research services; medical and pharmacological research services; pharmaceutical products development; development of pharmaceutical preparations and medicines; consultancy relating to pharmaceutical research and development; provision of medical research services; scientific research; medical research; biomedical research services; research relating to biotechnology; research on the subject of pharmaceuticals; consultancy relating to research in the field of pharmacogenetics; research and development in the pharmaceutical and biotechnology fields; research and development in the field of diagnostic preparations; research and development in the field of biotechnology; pharmaceutical research and development for the pharmaceutical industry; research and development services in the field of antibody technology; research and development services in the field of antibodies; scientific laboratory services relating to the production of monoclonal antibodies; all the aforesaid goods exclusively relating to the fields of oncology and/or immunosuppression
Classe 44
Pharmaceutical advice; pharmaceutical consultation services; consultancy and information services relating to pharmaceutical products; all the aforesaid goods exclusively relating to the fields of oncology and/or immunosuppression
Publicações
Histórico de despachos e eventos da marca no USPTO.
54 publicações encontradas
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
04/02/2025
EWOR
TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
04/02/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
04/02/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
04/02/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
04/02/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
04/02/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
01/11/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
01/11/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
16/08/2022
PUBO
PUBLISHED FOR OPPOSITION
16/08/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
27/07/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/07/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/07/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/07/2022
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
05/07/2022
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
13/01/2022
GNFR
FINAL REFUSAL E-MAILED
13/01/2022
CNFR
FINAL REFUSAL WRITTEN
13/01/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
29/11/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
29/11/2021
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
15/11/2021
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
05/10/2021
GNSI
INQUIRY TO SUSPENSION E-MAILED
05/10/2021
CNSI
SUSPENSION INQUIRY WRITTEN
05/10/2021
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
25/08/2021
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
05/01/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
05/01/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
05/01/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
05/01/2021
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
05/01/2021
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
07/12/2020
GNSL
LETTER OF SUSPENSION E-MAILED
07/12/2020
CNSL
SUSPENSION LETTER WRITTEN
07/12/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/12/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/12/2020
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
25/11/2020
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
23/11/2020
GNSI
INQUIRY TO SUSPENSION E-MAILED
23/11/2020
CNSI
SUSPENSION INQUIRY WRITTEN
23/11/2020
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
02/11/2020
ALIE
ASSIGNED TO LIE
02/11/2020
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
26/02/2020
GNSL
LETTER OF SUSPENSION E-MAILED
26/02/2020
CNSL
SUSPENSION LETTER WRITTEN
26/02/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/02/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/02/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/02/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
09/08/2019
GNRT
NON-FINAL ACTION E-MAILED
09/08/2019
CNRT
NON-FINAL ACTION WRITTEN
09/08/2019
DOCK
ASSIGNED TO EXAMINER
08/08/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
05/06/2019
NWAP
NEW APPLICATION ENTERED
24/05/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ATAC ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.